ImmunoGenesis, Inc. logo

ImmunoGenesis, Inc.

Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mechanisms of immune resistance.

14 employees · est. 2019 · Houston, United States

VS
Sling Therapeutics logo

Sling Therapeutics

Focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED).

12 employees · est. 2020 · Ann Arbor, United States

ImmunoGenesis, Inc. is the older company (2019 vs 2020).

Side-by-Side Comparison

ImmunoGenesis, Inc. Sling Therapeutics
Founded
2019 older 2020
Headquarters
Houston, United States Ann Arbor, United States
Employees
14 12
Industry
Biotechnology, Health Care, Health and Wellness Biopharma, Biotechnology, Pharmaceutical
Funding Stage
Series Unknown Series A
Total Funding
$28.00M $35.00M
Funding Rounds
4 1
Services
Not tracked yet Development of Linsitinib for Thyroid Eye Disease, Conducting Clinical Trials, Therapeutic Pipeline Development, Medical Research and Innovation
Target Customers
Not tracked yet Patients with Thyroid Eye Disease, Caregivers, Healthcare Providers, Medical Researchers
Taxonomy
Immuno-oncology, Biopharmaceutical, Drug Development, Immune Resistance, Immune-excluded Tumors, Immunotherapy, Clinical-stage, Immune Response, Tumor Pathology, Cancer Treatment, Immune System, Therapy Development Thyroid Eye Disease, Biopharmaceutical, Clinical-stage Development, Oral Small Molecule, Drug Development, Autoimmune Diseases, Endocrinology, Ophthalmology, Hyperthyroidism, Clinical Research, Molecular Engineering, Chemistry, Patient Advocacy, Graves' Disease
Website
immunogenesis.com slingtx.com
ImmunoGenesis, Inc. logo

About ImmunoGenesis, Inc.

ImmunoGenesis, Inc. is a clinical-stage immuno-oncology biopharmaceutical company focused on re-envisioning the treatment of "cold" tumors, particularly immune-excluded tumors. These tumors, which account for over half of all cancers, are resistant to current immunotherapies due to mechanisms that s...

Sling Therapeutics logo

About Sling Therapeutics

Sling Therapeutics, a clinical-stage company founded in 2020, is making significant strides in the biopharma and biotechnology industries. The company is headquartered in the United States and focuses on the late-stage development of an oral small molecule designed to treat thyroid eye disease (TED)...

We will tell you when either one moves

BounceWatch watches ImmunoGenesis, Inc. and Sling Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at ImmunoGenesis, Inc. and Sling Therapeutics — by email.

Frequently Asked Questions

ImmunoGenesis, Inc. — Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mechanisms of immune resistance.. Sling Therapeutics — Focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED).. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
ImmunoGenesis, Inc. has raised $28.00M while Sling Therapeutics has raised $35.00M.
ImmunoGenesis, Inc. and Sling Therapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare ImmunoGenesis, Inc. with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at ImmunoGenesis, Inc. on 12 Sep 2024, and Sling Therapeutics on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy